Stryker Corporation $SYK Shares Sold by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI cut its stake in Stryker Corporation (NYSE:SYK) by 39.8% in the first quarter, HoldingsChannel reports. The firm owned 13,928 shares of the medical technology company’s stock after selling 9,209 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Stryker were worth $4,577,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Godfrey Financial Associates Inc. acquired a new stake in Stryker in the 4th quarter valued at about $26,000. Sankala Group LLC purchased a new position in shares of Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the third quarter worth about $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker during the fourth quarter worth approximately $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Stryker during the fourth quarter worth approximately $28,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 0.3%

Shares of Stryker stock opened at $318.80 on Tuesday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a fifty day simple moving average of $313.41 and a 200-day simple moving average of $336.46. The stock has a market cap of $122.22 billion, a price-to-earnings ratio of 36.90, a PEG ratio of 2.05 and a beta of 0.77. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the business earned $2.84 earnings per share. Stryker’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Analyst Ratings Changes

A number of research analysts recently issued reports on SYK shares. Truist Financial reiterated a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Citigroup reduced their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, JPMorgan Chase & Co. dropped their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $392.52.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 323,264 shares of company stock valued at $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.